Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT?

Research

Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT? / Gaede, Peter; Pedersen, Oluf.

In: Nature clinical practice. Endocrinology & metabolism, Vol. 3, No. 6, 2007, p. 456-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Gaede, P & Pedersen, O 2007, 'Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT?', Nature clinical practice. Endocrinology & metabolism, vol. 3, no. 6, pp. 456-7. https://doi.org/10.1038/ncpendmet0503

APA

Gaede, P., & Pedersen, O. (2007). Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT? Nature clinical practice. Endocrinology & metabolism, 3(6), 456-7. https://doi.org/10.1038/ncpendmet0503

Vancouver

Gaede P, Pedersen O. Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT? Nature clinical practice. Endocrinology & metabolism. 2007;3(6):456-7. https://doi.org/10.1038/ncpendmet0503

Author

Gaede, Peter ; Pedersen, Oluf. / Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT?. In: Nature clinical practice. Endocrinology & metabolism. 2007 ; Vol. 3, No. 6. pp. 456-7.

Bibtex

@article{9199802c8997476c8d6d32b2a00231df,

title = "Rosiglitazone monotherapy for type 2 diabetes mellitus-too soon to ADOPT?",

author = "Peter Gaede and Oluf Pedersen",

year = "2007",

doi = "10.1038/ncpendmet0503",

language = "English",

volume = "3",

pages = "456--7",

journal = "Nature Clinical Practice Endocrinology and Metabolism",

issn = "1745-8366",

publisher = "Nature Publishing Group",

number = "6",